Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) Shares Sold by Dakota Wealth Management

Dakota Wealth Management decreased its stake in Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) by 2.2% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 9,070 shares of the company’s stock after selling 200 shares during the quarter. Dakota Wealth Management owned approximately 0.22% of Invesco Biotechnology & Genome ETF worth $603,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of the stock. Cetera Investment Advisers increased its holdings in shares of Invesco Biotechnology & Genome ETF by 2.1% during the 2nd quarter. Cetera Investment Advisers now owns 27,893 shares of the company’s stock worth $1,808,000 after buying an additional 561 shares during the last quarter. Massachusetts Wealth Management increased its position in shares of Invesco Biotechnology & Genome ETF by 7.3% during the 3rd quarter. Massachusetts Wealth Management now owns 18,184 shares of the company’s stock worth $1,270,000 after purchasing an additional 1,240 shares during the last quarter. IHT Wealth Management LLC boosted its stake in Invesco Biotechnology & Genome ETF by 14.7% during the third quarter. IHT Wealth Management LLC now owns 12,124 shares of the company’s stock worth $847,000 after buying an additional 1,550 shares during the period. HighTower Advisors LLC raised its stake in shares of Invesco Biotechnology & Genome ETF by 64.1% in the 3rd quarter. HighTower Advisors LLC now owns 7,101 shares of the company’s stock valued at $494,000 after acquiring an additional 2,774 shares during the period. Finally, Creative Financial Designs Inc. ADV raised its position in Invesco Biotechnology & Genome ETF by 5.6% in the third quarter. Creative Financial Designs Inc. ADV now owns 5,630 shares of the company’s stock valued at $393,000 after purchasing an additional 299 shares during the period.

Invesco Biotechnology & Genome ETF Stock Down 0.3 %

PBE opened at $69.04 on Friday. Invesco Biotechnology & Genome ETF has a 52 week low of $59.32 and a 52 week high of $72.84. The business has a fifty day simple moving average of $68.43 and a 200-day simple moving average of $69.12. The firm has a market cap of $278.92 million, a P/E ratio of 17.12 and a beta of 0.88.

Invesco Biotechnology & Genome ETF Company Profile

PowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index). The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies.